Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients (CERTES02)

Novartis logo

Novartis

Status and phase

Completed
Phase 3

Conditions

Organ Transplantation, Renal Transplantation

Treatments

Drug: Everolimus (Certican)
Drug: Cyclosporine (Neoral)
Drug: Steroid
Drug: Basiliximab (Simulect)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00154284
CRAD001A2419
CRAD001A2423 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of everolimus in combination with basiliximab, and steroids with and without cyclosporine microemulsion in de novo kidney transplant recipients.

Full description

This is a combined analysis using 81 patients randomized and treated in CRAD001A2419 (NCT00154284) with 33 randomized and treated in CRAD001A2423 (NCT00170807). This approach is reflected in the protocol amendments for each study, and the one clinical study report for both.

Enrollment

114 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Recipients of a first renal transplant from a primary cadaveric or non-HLA identical living related donor.
  • Renal cold ischemic time < 36 hours.
  • Age of donor < 65 years.

Exclusion criteria

  • Patients who have received an investigational drug within 4 weeks of baseline period.
  • Patients who are recipients of multiple organ transplants, including any organ other than kidney.
  • Recipients of non-heart beating donor organs.

Other protocol-defined exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

114 participants in 2 patient groups

Everolimus (Certican) with Cyclosporine (Neoral) Continuation
Active Comparator group
Description:
Patients were treated with everolimus and cyclosporine for 3 months post-transplantation. Everolimus (Certican) was administered orally, in two divided doses (b.i.d), and at the same time as Cyclosporine (Neoral). Everolimus (Certican) dose was adjusted in order to maintain a trough level between 3 and 8 ng/mL until randomization. After randomization the target trough range remained at 3 - 8 ng/mL in the cyclosporine (Neoral) continuation groups for a period of 9 months. Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
Treatment:
Drug: Basiliximab (Simulect)
Drug: Steroid
Drug: Cyclosporine (Neoral)
Drug: Everolimus (Certican)
Everolimus (Certican) with Cyclosporine (Neoral) Withdrawal
Experimental group
Description:
Patients were treated with everolimus and cyclosporine for 3 months post-transplantation. Everolimus (Certican) was administered orally, in two divided doses (b.i.d), and at the same time as Cyclosporine (Neoral). Everolimus (Certican) dose was adjusted in order to maintain a trough level between 3 and 8 ng/mL until randomization. Therefore, patients were randomized to cyclosporine withdrawal over a period of 1 month (±1 week) in study A2419 (NCT00154284) and over 3 months (±1 week) in study A2423 (NCT00170807). After randomization, final target trough range for everolimus was 8 - 12 ng/mL. Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
Treatment:
Drug: Basiliximab (Simulect)
Drug: Steroid
Drug: Cyclosporine (Neoral)
Drug: Everolimus (Certican)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems